Monitor

What just changed and what’s coming. Actual and guided are never confused.

All eventsGuided onlyActual onlyTrial Readout (864)Corporate Filing (685)Label Expansion (60)Guided Milestone (4)Regulatory Action (22)Congress Presentation (19)
250 events
2026-06-22
AbbVie — 8-K filed
Corporate Filing
2026-06-10
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-06-09
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-06-08
Metformin Treatment on Cognitive Impairment of Schizophrenia — primary completion
Trial Readout · NCT05838573
2026-05-29
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-12
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-12
AbbVie — 8-K filed
Corporate Filing
2026-05-08
Bristol-Myers — 8-K filed
Corporate Filing
2026-05-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-01
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-01
Lumateperone late_breaking at NEI 2026
Congress Presentation · Lumateperone (Caplyta)
2026-04-30
Bristol-Myers — 8-K filed
Corporate Filing
2026-04-29
AbbVie — 8-K filed
Corporate Filing
2026-04-28
Johnson & Johnson — 8-K filed
Corporate Filing
2026-04-27
NUPLAZID — efficacy supplement approved
Label Expansion · Pimavanserin
2026-04-24
CAPLYTA — efficacy supplement approved
Label Expansion · Lumateperone (Caplyta)
2026-04-24
Lumateperone — FDA efficacy supplement (label expansion) (SUPPL17)
Regulatory Action · Lumateperone (Caplyta)
2026-04-14
Johnson & Johnson — 8-K filed
Corporate Filing
2026-04-06
LB Pharmaceuticals Inc. — S-1 filed
Corporate Filing
2026-04-03
AbbVie — 8-K filed
Corporate Filing
2026-03-26
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-16
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-10
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-05
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-04
AbbVie — 8-K filed
Corporate Filing
2026-03-01
LB-102 poster at SIRS 2026
Congress Presentation · LB-102
2026-03-01
LB-102 oral at SIRS 2026
Congress Presentation · LB-102
2026-02-26
AbbVie — 8-K filed
Corporate Filing
2026-02-25
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-02-05
Bristol-Myers — 8-K filed
Corporate Filing
2026-02-05
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-02-04
AbbVie — 8-K filed
Corporate Filing
2026-01-30
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone — primary completion
Trial Readout · NCT07575516
2026-01-21
Johnson & Johnson — 8-K filed
Corporate Filing
2026-01-13
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-01-12
Bristol-Myers — 8-K filed
Corporate Filing
2026-01-07
AbbVie — 8-K filed
Corporate Filing
2026-01-02
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults Wit — primary completion
Trial Readout · NCT07550387
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL15)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL14)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
VRAYLAR — efficacy supplement approved
Label Expansion · Cariprazine (Vraylar)
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL16)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL17)
Regulatory Action · Cariprazine (Vraylar)
2025-11-25
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use — primary completion
Trial Readout · NCT04105231
2025-11-18
Bristol-Myers — 8-K filed
Corporate Filing
2025-11-13
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-12
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-10
Bristol-Myers — 8-K filed
Corporate Filing
2025-11-06
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-05
CAPLYTA — efficacy supplement approved
Label Expansion · Lumateperone (Caplyta)
2025-11-05
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-05
Lumateperone — FDA efficacy supplement (label expansion) (SUPPL16)
Regulatory Action · Lumateperone (Caplyta)
2025-11-03
Bristol-Myers — 8-K filed
Corporate Filing
2025-11-03
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-10-31
AbbVie — 8-K filed
Corporate Filing
2025-10-30
Bristol-Myers — 8-K filed
Corporate Filing
2025-10-14
Johnson & Johnson — 8-K filed
Corporate Filing
2025-10-07
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia — primary completion
Trial Readout · NCT07116694
2025-10-06
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabilit — primary completion
Trial Readout · NCT04578756
2025-10-03
AbbVie — 8-K filed
Corporate Filing
2025-10-01
LB-102 poster at ECNP 2025
Congress Presentation · LB-102
2025-10-01
LB-102 poster at ECNP 2025
Congress Presentation · LB-102
2025-10-01
LB-102 poster at ECNP 2025
Congress Presentation · LB-102
2025-10-01
Lumateperone poster at ECNP 2025
Congress Presentation · Lumateperone (Caplyta)
2025-09-12
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-09-12
LB Pharmaceuticals Inc. — 424B4 filed
Corporate Filing
2025-09-11
AbbVie — 8-K filed
Corporate Filing
2025-09-09
Johnson & Johnson — 8-K filed
Corporate Filing
2025-08-22
LB Pharmaceuticals Inc. — S-1 filed
Corporate Filing
2025-08-15
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and — primary completion
Trial Readout · NCT05658510
2025-08-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-07-31
Bristol-Myers — 8-K filed
Corporate Filing
2025-07-31
AbbVie — 8-K filed
Corporate Filing
2025-07-25
Bristol-Myers — 8-K filed
Corporate Filing
2025-07-16
Johnson & Johnson — 8-K filed
Corporate Filing
2025-07-03
AbbVie — 8-K filed
Corporate Filing
2025-06-25
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Pa — primary completion
Trial Readout · NCT05443724
2025-06-20
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Sym — primary completion
Trial Readout · NCT05838625
2025-06-13
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment — primary completion
Trial Readout · NCT06067984
2025-06-10
Johnson & Johnson — 8-K filed
Corporate Filing
2025-06-10
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-29
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-20
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-13
AbbVie — 8-K filed
Corporate Filing
2025-05-09
Brexpiprazole — FDA efficacy supplement (label expansion) (SUPPL14)
Regulatory Action · Brexpiprazole (Rexulti)
2025-05-09
REXULTI — efficacy supplement approved
Label Expansion · Brexpiprazole (Rexulti)
2025-05-07
Bristol-Myers — 8-K filed
Corporate Filing
2025-05-07
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-01
LB-102 poster at ASCP 2025
Congress Presentation · LB-102
2025-04-30
Johnson & Johnson — 8-K filed
Corporate Filing
2025-04-25
AbbVie — 8-K filed
Corporate Filing
2025-04-24
Bristol-Myers — 8-K filed
Corporate Filing
2025-04-22
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance — primary completion
Trial Readout · NCT03238326
2025-04-16
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-04-15
Johnson & Johnson — 8-K filed
Corporate Filing
2025-04-09
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated W — primary completion
Trial Readout · NCT05686239
2025-04-03
Johnson & Johnson — 8-K filed
Corporate Filing
2025-04-03
AbbVie — 8-K filed
Corporate Filing
2025-04-02
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-04-01
LB-102 poster at SIRS 2025
Congress Presentation · LB-102
2025-04-01
R33: Levetiracetam in Early Psychosis — primary completion
Trial Readout · NCT04317807
2025-03-30
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT04857983
2025-03-27
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-03-19
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inade — primary completion
Trial Readout · NCT05145413
2025-03-18
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-03-13
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effe — primary completion
Trial Readout · NCT06572449
2025-03-03
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-02-28
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and In — primary completion
Trial Readout · NCT07477301
2025-02-26
AbbVie — 8-K filed
Corporate Filing
2025-02-26
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who — primary completion
Trial Readout · NCT05211947
2025-02-26
Johnson & Johnson — 8-K filed
Corporate Filing
2025-02-26
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-02-21
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-02-20
Johnson & Johnson — 8-K filed
Corporate Filing
2025-02-19
AbbVie — 8-K filed
Corporate Filing
2025-02-18
Bristol-Myers — 8-K filed
Corporate Filing
2025-02-14
AbbVie — 8-K filed
Corporate Filing
2025-02-06
Bristol-Myers — 8-K filed
Corporate Filing
2025-02-05
AbbVie — 8-K filed
Corporate Filing
2025-02-04
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as — primary completion
Trial Readout · NCT05110157
2025-01-31
AbbVie — 8-K filed
Corporate Filing
2025-01-22
Johnson & Johnson — 8-K filed
Corporate Filing
2025-01-13
Bristol-Myers — 8-K filed
Corporate Filing
2025-01-13
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-01-10
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-01-10
AbbVie — 8-K filed
Corporate Filing
2025-01-06
AbbVie — 8-K filed
Corporate Filing
2024-12-30
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT04414930
2024-12-13
AbbVie — 8-K filed
Corporate Filing
2024-12-11
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-12-04
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB — primary completion
Trial Readout · NCT06179108
2024-12-03
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-12-02
The Sub-Sero Study — primary completion
Trial Readout · NCT03994965
2024-12-01
Lumateperone presentation at ACNP 2024
Congress Presentation · Lumateperone (Caplyta)
2024-11-20
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-11-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-11-05
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-10-31
Bristol-Myers — 8-K filed
Corporate Filing
2024-10-30
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-10-30
AbbVie — 8-K filed
Corporate Filing
2024-10-28
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in Peo — primary completion
Trial Readout · NCT04860830
2024-10-18
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion
Trial Readout · NCT04846881
2024-10-15
Johnson & Johnson — 8-K filed
Corporate Filing
2024-10-03
AbbVie — 8-K filed
Corporate Filing
2024-09-26
Xanomeline-trospium — FDA original approval (ORIG1)
Regulatory Action · Xanomeline-trospium (Cobenfy)
2024-09-26
COBENFY — first US approval (Xanomeline-trospium (Cobenfy))
Regulatory Approval · Xanomeline-trospium (Cobenfy)
2024-09-23
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-09-23
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania — primary completion
Trial Readout · NCT03383874
2024-09-23
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effect — primary completion
Trial Readout · NCT05741528
2024-09-20
Johnson & Johnson — 8-K filed
Corporate Filing
2024-09-20
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazin — primary completion
Trial Readout · NCT05368558
2024-09-17
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion
Trial Readout · NCT04846868
2024-09-16
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospital — primary completion
Trial Readout · NCT05919823
2024-09-16
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a — primary completion
Trial Readout · NCT02088060
2024-09-10
Johnson & Johnson — 8-K filed
Corporate Filing
2024-09-10
AbbVie — 8-K filed
Corporate Filing
2024-08-26
Johnson & Johnson — 8-K filed
Corporate Filing
2024-08-23
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion
Trial Readout · NCT05227690
2024-08-21
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Function — primary completion
Trial Readout · NCT05414058
2024-08-15
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion
Trial Readout · NCT05227703
2024-08-14
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophren — primary completion
Trial Readout · NCT04013555
2024-08-07
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-08-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-07-26
Bristol-Myers — 8-K filed
Corporate Filing
2024-07-25
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia — primary completion
Trial Readout · NCT04959032
2024-07-25
AbbVie — 8-K filed
Corporate Filing
2024-07-17
Johnson & Johnson — 8-K filed
Corporate Filing
2024-07-10
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults Wi — primary completion
Trial Readout · NCT05545111
2024-07-03
AbbVie — 8-K filed
Corporate Filing
2024-06-30
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia — primary completion
Trial Readout · NCT03034356
2024-06-28
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Part — primary completion
Trial Readout · NCT05182476
2024-06-21
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episod — primary completion
Trial Readout · NCT04624243
2024-06-18
Bristol-Myers — 8-K filed
Corporate Filing
2024-06-18
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-06-18
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-06-05
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in P — primary completion
Trial Readout · NCT05278156
2024-06-01
Sodium Nitroprusside in Early Course Schizophrenia — primary completion
Trial Readout · NCT04986072
2024-05-31
Substance Misuse To Psychosis for Stimulants — primary completion
Trial Readout · NCT03485417
2024-05-29
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-05-24
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy o — primary completion
Trial Readout · NCT04820309
2024-05-20
Johnson & Johnson — 8-K filed
Corporate Filing
2024-05-17
Johnson & Johnson — 8-K filed
Corporate Filing
2024-05-09
Bristol-Myers — 8-K filed
Corporate Filing
2024-05-08
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-05-07
Brexpiprazole — FDA efficacy supplement (label expansion) (SUPPL11)
Regulatory Action · Brexpiprazole (Rexulti)
2024-05-07
REXULTI — efficacy supplement approved
Label Expansion · Brexpiprazole (Rexulti)
2024-05-07
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-05-01
LB-102 poster at ASCP 2024
Congress Presentation · LB-102
2024-05-01
Johnson & Johnson — 8-K filed
Corporate Filing
2024-04-30
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia — primary completion
Trial Readout · NCT03121586
2024-04-29
Johnson & Johnson — 8-K filed
Corporate Filing
2024-04-26
AbbVie — 8-K filed
Corporate Filing
2024-04-25
Bristol-Myers — 8-K filed
Corporate Filing
2024-04-24
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-04-18
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-04-16
Johnson & Johnson — 8-K filed
Corporate Filing
2024-04-16
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-04-16
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-04-03
AbbVie — 8-K filed
Corporate Filing
2024-04-02
FANAPT — efficacy supplement approved
Label Expansion · Iloperidone
2024-04-01
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-04-01
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is — primary completion
Trial Readout · NCT05628103
2024-03-26
The Effectiveness and Efficacy of the Combination of the Integrated Psychologica — primary completion
Trial Readout · NCT05623228
2024-03-25
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia — primary completion
Trial Readout · NCT05643196
2024-03-22
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Parti — primary completion
Trial Readout · NCT04457310
2024-03-21
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 — primary completion
Trial Readout · NCT05359081
2024-03-19
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-03-19
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Te — primary completion
Trial Readout · NCT05693935
2024-03-18
Bristol-Myers — 8-K filed
Corporate Filing
2024-03-18
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Predi — primary completion
Trial Readout · NCT05193578
2024-03-18
Bristol-Myers — 8-K filed
Corporate Filing
2024-03-11
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-02-27
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-02-26
AbbVie — 8-K filed
Corporate Filing
2024-02-23
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients — primary completion
Trial Readout · NCT03943537
2024-02-22
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-02-22
Bristol-Myers — 8-K filed
Corporate Filing
2024-02-20
AbbVie — 8-K filed
Corporate Filing
2024-02-15
Bristol-Myers — 8-K filed
Corporate Filing
2024-02-14
Bristol-Myers — 8-K filed
Corporate Filing
2024-02-12
AbbVie — 8-K filed
Corporate Filing
2024-02-02
Bristol-Myers — 8-K filed
Corporate Filing
2024-02-02
AbbVie — 8-K filed
Corporate Filing
2024-01-31
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Respon — primary completion
Trial Readout · NCT03900754
2024-01-31
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-01-25
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Sym — primary completion
Trial Readout · NCT04531982
2024-01-23
Johnson & Johnson — 8-K filed
Corporate Filing
2024-01-08
Bristol-Myers — 8-K filed
Corporate Filing
2024-01-05
AbbVie — 8-K filed
Corporate Filing
2023-12-31
Pharmacological Modulation of Hippocampal Activity in Psychosis 2 — primary completion
Trial Readout · NCT04559529
2023-12-22
Bristol-Myers — 8-K filed
Corporate Filing
2023-12-06
AbbVie — 8-K filed
Corporate Filing
2023-12-05
Johnson & Johnson — 8-K filed
Corporate Filing
2023-12-05
Johnson & Johnson — 8-K filed
Corporate Filing
2023-11-30
AbbVie — 8-K filed
Corporate Filing
2023-11-30
Johnson & Johnson — 8-K filed
Corporate Filing
2023-11-29
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophre — primary completion
Trial Readout · NCT02261519
2023-11-27
Johnson & Johnson — 8-K filed
Corporate Filing
2023-11-21
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2023-11-13
Bristol-Myers — 8-K filed
Corporate Filing
2023-11-09
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investi — primary completion
Trial Readout · NCT04109950
2023-11-08
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Ad — primary completion
Trial Readout · NCT05654870
2023-11-03
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acti — primary completion
Trial Readout · NCT05779241
2023-11-02
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2023-11-02
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2023-10-27
AbbVie — 8-K filed
Corporate Filing
2023-10-26
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® — primary completion
Trial Readout · NCT01908192
2023-10-26
Bristol-Myers — 8-K filed
Corporate Filing
2023-10-23
Johnson & Johnson — 8-K filed
Corporate Filing
2023-10-17
Johnson & Johnson — 8-K filed
Corporate Filing